SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Abhishek Kansara; Faiza Mubeen; Jawairia Shakil

doi:10.14797/mdcvj.1120

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review

Methodist DeBakey Cardiovascular Journal

Volume 18 (2022): Issue 4

By: Abhishek Kansara , Faiza Mubeen and Jawairia Shakil

Open Access

|Sep 2022

Abstract

Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.

References

Chao EC. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes. 2014 Jan;32(1):4–11. doi: 10.2337/diaclin.32.1.4
Open DOI Search in Google Scholar Back to article
Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015 Mar;12(2):78–89. doi: 10.1177/1479164114561992
Open DOI Search in Google Scholar Back to article
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75(1):33–59. doi: 10.1007/s40265-014-0337-y
Open DOI Search in Google Scholar Back to article
Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes. 2020 Jan 21;13:161–174. doi: 10.2147/DMSO.S233538
Open DOI Search in Google Scholar Back to article
Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021 Jan;77(1):94–109. doi: 10.1053/j.ajkd.2020.08.003
Open DOI Search in Google Scholar Back to article
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323–34. doi: 10.1056/NEJMoa1515920
Open DOI Search in Google Scholar Back to article
Sarraju A, Li J, Cannon CP, et al. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 Mar;233:141–148. doi: 10.1016/j.ahj.2020.12.008
Open DOI Search in Google Scholar Back to article
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
Open DOI Search in Google Scholar Back to article
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129–139. doi: 10.1056/NEJMoa2030186
Open DOI Search in Google Scholar Back to article
Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. 2019 Jun;42(6):1067–1074. doi: 10.2337/dc19-0093
Open DOI Search in Google Scholar Back to article
AlKindi F, Al-Omary HL, Hussain Q, Al Hakim M, Chaaban A, Boobes Y. Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients. Transplant Proc. 2020 Jan-Feb;52(1):175–178. doi: 10.1016/j.transproceed.2019.11.007
Open DOI Search in Google Scholar Back to article
Patel N, Hindi J, Farouk SS. Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For? Kidney360. 2021 Apr 22;2(7):1174–1178. doi: 10.34067/KID.0000732021
Open DOI Search in Google Scholar Back to article
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6
Open DOI Search in Google Scholar Back to article
Sarwar N, Gao P, Seshasai SRK, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9
Open DOI Search in Google Scholar Back to article
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28. doi: 10.1056/NEJMoa1504720
Open DOI Search in Google Scholar Back to article
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644–657. doi: 10.1056/NEJMoa1611925
Open DOI Search in Google Scholar Back to article
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
Open DOI Search in Google Scholar Back to article
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
Open DOI Search in Google Scholar Back to article
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
Open DOI Search in Google Scholar Back to article
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117–128. doi: 10.1056/NEJMoa2030183
Open DOI Search in Google Scholar Back to article
Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933
Open DOI Search in Google Scholar Back to article
McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021 Feb 1;6(2):148–158. doi: 10.1001/jamacardio.2020.4511
Open DOI Search in Google Scholar Back to article
Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 Nov;27(11):1954–1960. doi: 10.1038/s41591-021-01536-x
Open DOI Search in Google Scholar Back to article
Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022 Apr;28(4):809–813. doi: 10.1038/s41591-022-01703-8
Open DOI Search in Google Scholar Back to article
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752–72. doi: 10.1161/CIRCULATIONAHA.116.021887
Open DOI Search in Google Scholar Back to article
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017 Feb;60(2):215–225. doi: 10.1007/s00125-016-4157-3
Open DOI Search in Google Scholar Back to article
Tonneijck L, Muskiet MHA, Smits MM, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol. 2017 Apr;28(4):1023–1039. doi: 10.1681/ASN.2016060666
Open DOI Search in Google Scholar Back to article
Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020 Jun;16(6):317–336. doi: 10.1038/s41581-020-0256-y
Open DOI Search in Google Scholar Back to article
Corrigendum to “van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.” Kidney Int. 2020 May;97(5):1061. doi: 10.1016/j.kint.2020.03.009
Open DOI Search in Google Scholar Back to article
Wang C, Zhou Y, Kong Z, et al. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019 Apr;21(4):1018–1026. doi: 10.1111/dom.13620
Open DOI Search in Google Scholar Back to article
Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018 May 1;314(5):F969–F984. doi: 10.1152/ajprenal.00551.2017
Open DOI Search in Google Scholar Back to article
Sas KM, Kayampilly P, Byun J, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight. 2016 Sep 22;1(15):e86976. doi: 10.1172/jci.insight.86976
Open DOI Search in Google Scholar Back to article
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018 Mar;20(3):479–487. doi: 10.1111/dom.13126
Open DOI Search in Google Scholar Back to article
Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care. 2016 Nov;39(11):2036–2041. doi: 10.2337/dc15-2688
Open DOI Search in Google Scholar Back to article
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61(10):2108–2117. doi: 10.1007/s00125-018-4670-7
Open DOI Search in Google Scholar Back to article
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017 Mar;104:298–310. doi: 10.1016/j.freeradbiomed.2017.01.035
Open DOI Search in Google Scholar Back to article
Kang S, Verma S, Hassanabad AF, et al. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2020 Apr;36(4):543–553. doi: 10.1016/j.cjca.2019.08.033
Open DOI Search in Google Scholar Back to article
Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia. 2017 Feb;60(2):364–376. doi: 10.1007/s00125-016-4158-2
Open DOI Search in Google Scholar Back to article
Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014 Jan;306(2):F194–204. doi: 10.1152/ajprenal.00520.2013
Open DOI Search in Google Scholar Back to article
Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018 Aug;20(8):1988–1993. doi: 10.1111/dom.13301
Open DOI Search in Google Scholar Back to article
Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019 Jul;62(7):1154–1166. doi: 10.1007/s00125-019-4859-4
Open DOI Search in Google Scholar Back to article
Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012 Jan;35(1):99–104. doi: 10.2337/dc11-1346
Open DOI Search in Google Scholar Back to article
Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018 Feb;20(2):458–462. doi: 10.1111/dom.13101
Open DOI Search in Google Scholar Back to article
Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021 Feb 26;107(13):1032–1038. doi: 10.1136/heartjnl-2020-318060
Open DOI Search in Google Scholar Back to article
Sánchez-García A, Simental-Mendía M, Millán-Alanís JM, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020 Oct;160:105068. doi: 10.1016/j.phrs.2020.105068
Open DOI Search in Google Scholar Back to article
Storgaard H, Gluud LL, Bennett C, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125
Open DOI Search in Google Scholar Back to article
Adingupu DD, Göpel SO, Göpel J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob -/- mice. Cardiovasc Diabetol. 2019 Feb 7;18(1):16. doi: 10.1186/s12933-019-0820-6
Open DOI Search in Google Scholar Back to article
Kario K, Ferdinand KC, O’Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. May-Jun 2020;63(3):249–262. doi: 10.1016/j.pcad.2020.04.003
Open DOI Search in Google Scholar Back to article
Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019 Feb;79(3):219–230. doi: 10.1007/s40265-019-1057-0
Open DOI Search in Google Scholar Back to article
Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016 Aug;18(8):783–94. doi: 10.1111/dom.12670
Open DOI Search in Google Scholar Back to article
Cai X, Yang W, Gao X, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018 Jan;26(1):70–80. doi: 10.1002/oby.22066
Open DOI Search in Google Scholar Back to article
Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1730–5. doi: 10.2337/dc15-0355
Open DOI Search in Google Scholar Back to article
Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022 Jan;10(1):24–34. doi: 10.1016/S2213-8587(21)00295-3
Open DOI Search in Google Scholar Back to article
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111–S124. doi: 10.2337/dc21-S009
Open DOI Search in Google Scholar Back to article
Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012 Jul;28(7):1167–71. doi: 10.1185/03007995.2012.689956
Open DOI Search in Google Scholar Back to article
Zhou Y, Geng Z, Wang X, Huang Y, Shen L, Wang Y. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 2020 Feb;36(2):e3223. doi: 10.1002/dmrr.3223
Open DOI Search in Google Scholar Back to article
Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019 Jun 4;170(11):764–769. doi: 10.7326/M19-0085
Open DOI Search in Google Scholar Back to article
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347–357. doi: 10.1056/NEJMoa1812389
Open DOI Search in Google Scholar Back to article
Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochem Pharmacol. 2016 Feb 1;101:27–39. doi: 10.1016/j.bcp.2015.09.005
Open DOI Search in Google Scholar Back to article
Somagutta MR, Agadi K, Hange N, et al. Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers. Cureus. 2021 Mar 3;13(3):e13665. doi: 10.7759/cureus.13665
Open DOI Search in Google Scholar Back to article
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644–657. doi: 10.1056/NEJMoa1611925
Open DOI Search in Google Scholar Back to article
Vlachopoulos C, Terentes-Printzios D, Tsioufis K. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly. Eur Heart J. 2021 May 7;42(18):1739–1741. doi: 10.1093/eurheartj/ehaa1022
Open DOI Search in Google Scholar Back to article
Zhuo M, Hawley CE, Paik JM, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021 Oct 1;4(10):e2130762. doi: 10.1001/jamanetworkopen.2021.30762
Open DOI Search in Google Scholar Back to article
Scheen AJ. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opin Drug Saf. 2020 Mar;19(3):243–256. doi: 10.1080/14740338.2020.1733967
Open DOI Search in Google Scholar Back to article
Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med. 2019 Dec 9;16(12):e1002983. doi: 10.1371/journal.pmed.1002983
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcvj.1120 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 62 - 72

Submitted on: Apr 19, 2022

Accepted on: Jun 28, 2022

Published on: Sep 6, 2022

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

SGLT2 inhibitors,

cardiovascular outcomes,

renal outcomes,

heart failure,

diabetic ketoacidosis,

DKA

© 2022 Abhishek Kansara, Faiza Mubeen, Jawairia Shakil, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 18 (2022): Issue 4